## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims.

1. (Original) An (indol-3-yl)-heterocycle derivative having the general Formula I

$$R_{6}$$
 $R_{7}$ 
 $R_{2}$ 
 $R_{1}$ 
 $R_{2}$ 
Formula I

wherein

A represents a 5-membered aromatic heterocyclic ring, wherein  $X_1$ ,  $X_2$  and  $X_3$  are independently selected from N, O, S and CR;

R is H or (C<sub>1-4</sub>)alkyl; or

R, when present in  $X_2$  or  $X_3$ , may form together with  $R_3$  a 5-8 membered ring;

R<sub>1</sub> is a 5-8 membered saturated carbocyclic ring, optionally containing a heteroatom selected from O and S;

R<sub>2</sub> is H, CH<sub>3</sub> or CH<sub>2</sub>-CH<sub>3</sub>; or

 $R_2$  is joined together with  $R_7$  to form a 6-membered ring, optionally containing a heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring;  $R_3$  and  $R_4$  are independently H,  $(C_{1-6})$ alkyl or  $(C_{3-7})$ cycloalkyl, the alkyl groups being optionally substituted with OH,  $(C_{1-4})$ alkyloxy,  $(C_{1-4})$ alkylthio,  $(C_{1-4})$ alkylsulfonyl, CN or halogen; or  $R_3$  together with  $R_4$  and the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH,  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkyloxy,  $(C_{1-4})$ alkyloxy, or halogen; or

 $R_3$  together with  $R_5$  forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH,  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkyloxy,  $(C_{1-4})$ alkyl, or halogen; or

R<sub>3</sub> together with R, when present in X<sub>2</sub> or X<sub>3</sub> forms a 5-8 membered ring;

 $R_5$  is H or  $(C_{1-4})$ alkyl; or

 $R_5$  together with  $R_3$  forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH,  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkyloxy,  $(C_{1-4})$ alkyloxy-  $(C_{1-4})$ alkyl, or halogen;

 $R_5$ ' is H or  $(C_{1-4})$ alkyl;

R<sub>6</sub> represents 1-3 substituents independently selected from H, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy, CN and halogen;

R<sub>7</sub> is H, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyloxy, CN or halogen; or

R<sub>7</sub> is joined together with R<sub>2</sub> to form a 6-membered ring, optionally containing a further heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring; or a pharmaceutically acceptable salt thereof.

2. (Original) The (indol-3-yl)-heterocycle derivative of claim 1, wherein R₂ is H or is joined together with R₁ to form a 6-membered ring, optionally containing a heteroatom selected from O and S, and which atom is bonded to the 7-position of the indole ring.

- 3. (Currently Amended) The (indol-3-yl)-heterocycle derivative of claim 1 or  $\frac{2}{1}$ , wherein R, R<sub>5</sub>, R<sub>5</sub> and R<sub>6</sub> are H.
- 4. (Currently Amended) The (indol-3-yl)-heterocycle derivative of any one of claims 1-3 claim 1, wherein R<sub>1</sub> is cyclohexyl or tetrahydropyranyl.
- 5. (Currently Amended) The (indol-3-yl)-heterocycle derivative of any one of claims 1-4 claim 1 where the heterocycle A is 1,2,4-oxadiazole (X<sub>1</sub> is N, X<sub>2</sub> is O, X<sub>3</sub> is N), 1,2,4-thiadiazole (X<sub>1</sub> is N, X<sub>2</sub> is S, X<sub>3</sub> is N) or thiazole (X<sub>1</sub> is S, X<sub>2</sub> is CR, X<sub>3</sub> is N).
- 6. (Original) The (indol-3-yl)-heterocycle derivative of claim 1 which is selected from: -7-Chloro-3-(5-{[N-ethyl-N-(2-methoxyethyl)amino]methyl}-[1,2,4]-thiadiazol-3-yl)-1-

(tetrahydropyran-4-yl)methyl-1H-indole;

- 7-Chloro-3-{5-[(pyrrolidin-1-yl)methyl]-[1,2,4]-thiadiazol-3-yl}-1-(tetrahydropyran-4-yl)methyl-1*H*-indole:
- 7-Chloro-3-(5-{[*N*-ethyl-*N*-(2-hydroxyethyl)amino]methyl}-[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 7-Chloro-3-(4-{[N-(2-hydroxyethyl)-N-isopropylamino]methyl}-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 7-Chloro-3-(4-{[*N*-ethyl-*N*-(2-hydroxyethyl)amino]methyl}-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 7-Chloro-3-(4-{[N-(2-methoxyethyl)-N-methylamino]methyl}-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 7-Chloro-3-{5-[(2,2-dimethyl-pyrolidin-1-yl)methyl]-[1,2,4]oxadiazol-3-yl}-1-(tetrahydropyran-4-yl)methyl-1*H*-indole; or a pharmaceutically acceptable salt thereof.

## 7. (Cancelled)

- 8. (Currently Amended) A pharmaceutical composition comprising an (indol-3-yl)-heterocycle derivative of any one of claims 1-6 claim 1 in admixture with pharmaceutically acceptable auxiliaries.
- 9. (Cancelled)
- 10. (Currently Amended) A method of treatment of pain such as peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis, by comprising: administering to a patient in need thereof a therapeutically effective amount of an (indol-3-yl)-heterocycle derivative of any one of claims 1-6 claim 1.
- 11. (New) The method of claim 10, wherein the pain is selected from the group consisting of peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.
- 12. (New) A pharmaceutical composition comprising an (indol-3-yl)-heterocycle derivative of claim 5 in admixture with pharmaceutically acceptable auxiliaries.
- 13. (New) A pharmaceutical composition comprising an (indol-3-yl)-heterocycle derivative of claim 6 in admixture with pharmaceutically acceptable auxiliaries.
- 14. (New) A method of treatment of pain comprising: administering to a patient in need thereof a therapeutically effective amount of an (indol-3-yl)-heterocycle derivative of claim 5.

15. (New) A method of treatment of pain comprising: administering to a patient in need thereof a therapeutically effective amount of an (indol-3-yl)-heterocycle derivative of claim 6.